Cargando…
Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice
BACKGROUND: Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349441/ https://www.ncbi.nlm.nih.gov/pubmed/37452307 http://dx.doi.org/10.1186/s12967-023-04289-y |
_version_ | 1785073906320670720 |
---|---|
author | Li, Yue Wu, Ben Hossain, Md Jakir Quagliata, Lily O’Meara, Connor Wilkins, Marc R. Corley, Susan Khachigian, Levon M. |
author_facet | Li, Yue Wu, Ben Hossain, Md Jakir Quagliata, Lily O’Meara, Connor Wilkins, Marc R. Corley, Susan Khachigian, Levon M. |
author_sort | Li, Yue |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most patients and there are no approved small molecule inhibitors of the PD-1/PD-L1 system. Flubendazole (FLU) is an anthelmintic that has been used to treat worm infections in humans and animals for decades. METHODS: Here we tested the anti-cancer activity of systemically delivered FLU with suppression of PD-1 in immunocompetent mice. RESULTS: In C57BL/6J mice bearing subcutaneous B16F10 melanoma, FLU reduced both tumor growth and PD-1 protein levels without affecting levels of PD-L1. FLU’s suppression of PD-1 was accompanied by increased CD3(+) T cell infiltration. Western blotting with extracts from human Jurkat T cells showed that FLU inhibited PD-1 protein expression, findings confirmed by flow cytometry. To gain mechanistic insights on FLU’s ability to suppress PD-1 protein levels, we performed bulk RNA sequencing on extracts of Jurkat T cells exposed to the benzimidazole for 4 h. From a pool of 14,475 genes there were 1218 differentially-expressed genes; 687 with increased expression and 531 with decreased expression. Among the genes induced by FLU was the AP-1 family member, JUN and surprisingly, pdcd1. KEGG pathway analysis showed FLU up-regulated genes over-represented in multiple pathways (p < 0.01), the top hit being amoebiasis. FLU also affected the expression of genes in cancer-associated pathways, both through down-regulation and up-regulation. Gene set enrichment analysis revealed a large number of immunological signature gene sets correlated with FLU treatment, including gene sets associated with T cell differentiation, proliferation and function. The AP-1 inhibitor T5224 rescued PD-1 protein expression from inhibition by FLU. CONCLUSION: This study is the first to show that FLU can inhibit melanoma growth with PD-1 suppression in immunocompetent mice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04289-y. |
format | Online Article Text |
id | pubmed-10349441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103494412023-07-16 Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice Li, Yue Wu, Ben Hossain, Md Jakir Quagliata, Lily O’Meara, Connor Wilkins, Marc R. Corley, Susan Khachigian, Levon M. J Transl Med Research BACKGROUND: Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most patients and there are no approved small molecule inhibitors of the PD-1/PD-L1 system. Flubendazole (FLU) is an anthelmintic that has been used to treat worm infections in humans and animals for decades. METHODS: Here we tested the anti-cancer activity of systemically delivered FLU with suppression of PD-1 in immunocompetent mice. RESULTS: In C57BL/6J mice bearing subcutaneous B16F10 melanoma, FLU reduced both tumor growth and PD-1 protein levels without affecting levels of PD-L1. FLU’s suppression of PD-1 was accompanied by increased CD3(+) T cell infiltration. Western blotting with extracts from human Jurkat T cells showed that FLU inhibited PD-1 protein expression, findings confirmed by flow cytometry. To gain mechanistic insights on FLU’s ability to suppress PD-1 protein levels, we performed bulk RNA sequencing on extracts of Jurkat T cells exposed to the benzimidazole for 4 h. From a pool of 14,475 genes there were 1218 differentially-expressed genes; 687 with increased expression and 531 with decreased expression. Among the genes induced by FLU was the AP-1 family member, JUN and surprisingly, pdcd1. KEGG pathway analysis showed FLU up-regulated genes over-represented in multiple pathways (p < 0.01), the top hit being amoebiasis. FLU also affected the expression of genes in cancer-associated pathways, both through down-regulation and up-regulation. Gene set enrichment analysis revealed a large number of immunological signature gene sets correlated with FLU treatment, including gene sets associated with T cell differentiation, proliferation and function. The AP-1 inhibitor T5224 rescued PD-1 protein expression from inhibition by FLU. CONCLUSION: This study is the first to show that FLU can inhibit melanoma growth with PD-1 suppression in immunocompetent mice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04289-y. BioMed Central 2023-07-14 /pmc/articles/PMC10349441/ /pubmed/37452307 http://dx.doi.org/10.1186/s12967-023-04289-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Yue Wu, Ben Hossain, Md Jakir Quagliata, Lily O’Meara, Connor Wilkins, Marc R. Corley, Susan Khachigian, Levon M. Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice |
title | Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice |
title_full | Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice |
title_fullStr | Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice |
title_full_unstemmed | Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice |
title_short | Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice |
title_sort | flubendazole inhibits pd-1 and suppresses melanoma growth in immunocompetent mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349441/ https://www.ncbi.nlm.nih.gov/pubmed/37452307 http://dx.doi.org/10.1186/s12967-023-04289-y |
work_keys_str_mv | AT liyue flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice AT wuben flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice AT hossainmdjakir flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice AT quagliatalily flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice AT omearaconnor flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice AT wilkinsmarcr flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice AT corleysusan flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice AT khachigianlevonm flubendazoleinhibitspd1andsuppressesmelanomagrowthinimmunocompetentmice |